Inspire Medical Systems (NYSE:INSP) Upgraded by Zacks Research to “Strong-Buy” Rating

Inspire Medical Systems (NYSE:INSP) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Robert W. Baird increased their target price on Inspire Medical Systems from $54.00 to $59.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Mizuho upped their price target on shares of Inspire Medical Systems from $55.00 to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Piper Sandler upped their price objective on Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. UBS Group began coverage on shares of Inspire Medical Systems in a research note on Tuesday, July 28th. They issued a “sell” rating and a $39.00 price objective for the company. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $60.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $66.19.

Inspire Medical Systems Stock Performance

Shares of INSP opened at $57.43 on Monday. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03. The firm has a market cap of $1.66 billion, a P/E ratio of 12.43, a price-to-earnings-growth ratio of 4.34 and a beta of 0.70. The firm’s 50-day simple moving average is $49.98 and its 200 day simple moving average is $52.92.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. During the same period last year, the business posted $0.45 earnings per share. The business’s revenue for the quarter was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities analysts forecast that Inspire Medical Systems will post 1.24 earnings per share for the current year.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, insider Jason P. Kelly sold 963 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the transaction, the insider directly owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Inspire Medical Systems

A number of institutional investors and hedge funds have recently made changes to their positions in INSP. Royal Bank of Canada boosted its holdings in Inspire Medical Systems by 16.0% in the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after acquiring an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Inspire Medical Systems during the 1st quarter valued at approximately $524,000. Goldman Sachs Group Inc. raised its stake in Inspire Medical Systems by 57.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after acquiring an additional 18,857 shares during the period. Marshall Wace LLP lifted its position in shares of Inspire Medical Systems by 3.8% during the second quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock worth $2,064,000 after acquiring an additional 577 shares in the last quarter. Finally, Jump Financial LLC purchased a new position in Inspire Medical Systems during the 2nd quarter valued at about $931,000. Institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.